Slingshot members are tracking this event:
Interim look at the Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) by DSMB for recommendation to NINDS.
Do you think this event is important to the companies below? How will it affect their stock price?
"We look forward to providing further updates as we receive results of the interim analysis."
Slingshot Insights Explained
Dec 09, 2016
- Understanding the mechanism of action and public data for MN-166 (ibudilast) in Progressive MS in preparation for the Phase 2 interim analysis in the 4Q of 2016. MNOV, BIIB, RHHBY, MedDay Pharmaceuticals Executed On: Dec 12, 2016 at 11:30 AM EST
Related Keywords Mn-166, Ibudilast, Progressive Ms, Progressive Multiple Sclerosis, Ninds, Neuronext Trial, Sprint-ms